Predictions
Adaptimmune Therapeutics PLC ADR
Start price
Target price
Perf. (%)
€3.28
02.12.21
02.12.21
-
02.12.22
02.12.22
-0.61%
11.12.21
11.12.21
Risky Investment
TeamViewer AG
Start price
Target price
Perf. (%)
€11.00
02.12.21
02.12.21
€20.00
02.12.22
02.12.22
35.09%
03.02.22
03.02.22
Could be worthwhile Investment >10% per year
Higher risks for its business
TeamViewer AG
Start price
Target price
Perf. (%)
€11.00
02.12.21
02.12.21
€20.00
02.12.22
02.12.22
35.09%
03.02.22
03.02.22
Could be worthwhile Investment >10% per year
Higher risks for its business
TeamViewer AG
Start price
Target price
Perf. (%)
€12.49
02.12.21
02.12.21
-
-
02.12.21
02.12.21
Could be worthwhile Investment >10% per year
Higher risks for its business
TeamViewer AG
Start price
Target price
Perf. (%)
€12.49
02.12.21
02.12.21
-
-
02.12.21
02.12.21
Could be worthwhile Investment >10% per year
Higher risks for its business
Mercedes-Benz Group AG
Start price
Target price
Perf. (%)
€86.10
02.12.21
02.12.21
-
02.12.22
02.12.22
-0.82%
06.12.21
06.12.21
Known brand
Top 10 in its market
Valuable balance sheet
Revenue decline/stagnation expected
Mercedes-Benz Group AG
Start price
Target price
Perf. (%)
€86.10
02.12.21
02.12.21
-
02.12.22
02.12.22
-0.82%
06.12.21
06.12.21
Known brand
Top 10 in its market
Valuable balance sheet
Revenue decline/stagnation expected
Mercedes-Benz Group AG
Start price
Target price
Perf. (%)
€86.19
02.12.21
02.12.21
-
02.12.22
02.12.22
-0.10%
02.12.21
02.12.21
Known brand
Top 10 in its market
Valuable balance sheet
Revenue decline/stagnation expected
Mercedes-Benz Group AG
Start price
Target price
Perf. (%)
€86.19
02.12.21
02.12.21
-
02.12.22
02.12.22
-0.10%
02.12.21
02.12.21
Known brand
Top 10 in its market
Valuable balance sheet
Revenue decline/stagnation expected
Moderna Inc.
Start price
Target price
Perf. (%)
€274.00
01.12.21
01.12.21
€260.00
01.12.22
01.12.22
-15.33%
12.12.21
12.12.21
Revenue growth >5% per year expected
Differentiated customer and product portfolio
Future proof or reliable business model
Higher risks for its business
HelloFresh SE
Start price
Target price
Perf. (%)
€86.12
01.12.21
01.12.21
€65.00
01.12.22
01.12.22
-32.88%
10.01.22
10.01.22
Higher risks for its business
Accor S.A. Inh.
Start price
Target price
Perf. (%)
€26.64
01.12.21
01.12.21
€33.00
01.12.22
01.12.22
-4.69%
02.12.22
02.12.22
Could be worthwhile Investment >10% per year
Accor S.A. Inh.
Start price
Target price
Perf. (%)
€26.64
01.12.21
01.12.21
€33.00
01.12.22
01.12.22
-4.69%
02.12.22
02.12.22
Could be worthwhile Investment >10% per year
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€4.85
01.12.21
01.12.21
-
01.12.22
01.12.22
-53.67%
02.12.22
02.12.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
HelloFresh SE
Start price
Target price
Perf. (%)
€85.12
01.12.21
01.12.21
-
01.12.22
01.12.22
1.17%
01.12.21
01.12.21
Higher risks for its business
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.96
01.12.21
01.12.21
€6.00
01.12.22
01.12.22
-2.70%
11.12.21
11.12.21
Could be worthwhile Investment >10% per year
Innovative
Good culture
Below average Management
Krystal Biotech
Start price
Target price
Perf. (%)
€66.00
01.12.21
01.12.21
€50.00
31.12.23
31.12.23
16.67%
08.05.23
08.05.23
Could be very worthwhile Investment >20% year